ArticlePsychopharmacology2022
A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment.
Article in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Acute Effects of Ad Libitum Use of Commercially Available Cannabis Products on the Subjective Experience of Aerobic Exercise: A Crossover Study.Sports medicine (Auckland, N.Z.) · 2024Trial
- Chronic Δ9-Tetrahydrocannabinol Inhalation Following Osteoporosis Results in Bone Deficits.Biomedicines · 2026Article
- An Exploration of Heart Rate Response and Blood Tetrahydrocannabinol (THC) Levels to Commercially Available Cannabis Edibles by Dose.Research square · 2026Article
- Article
- Effects of legal-market cannabis and alcohol on verbal learning and memory.Psychopharmacology · 2026Article
- Effects of naturalistic doses of cannabis edibles on cognition and association with blood THC.Psychopharmacology · 2026Observational
- Experimental study on cannabis use and affect: Effects on reactivity to and recovery from negative stimuli.Journal of psychopathology and clinical science · 2025Article
- Quantity of delta-9-tetrahydrocannabinol consumption and cannabis use disorder among daily cannabis consumers.Addiction (Abingdon, England) · 2025Article
- Dose of Product or Product Concentration: A Comparison of Change in Heart Rate by THC Concentration for Participants Using Cannabis Daily and Occasionally.Cannabis and cannabinoid research · 2025Article
- Typical Hits, Grams, or Joints: Evaluating Cannabis Survey Measurement Strategies for Quantifying Consumption.Cannabis and cannabinoid research · 2024Article
- Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products.Cannabis and cannabinoid research · 2024Observational
- Cannabis use in context: Relations among impulsive personality traits, context, and cannabis problems.Addictive behaviors · 2023Article
- Characterization of cannabinoid plasma concentration, maternal health, and cytokine levels in a rat model of prenatal Cannabis smoke exposure.Scientific reports · 2023Article
- Sex Differences in Plasma, Adipose Tissue, and Central Accumulation of Cannabinoids, and Behavioral Effects of Oral Cannabis Consumption in Male and Female C57BL/6 Mice.The international journal of neuropsychopharmacology · 2023Article
- Evaluation of Radio Frequency-Assisted Enzymatic Extraction of Non-Anthocyanin Polyphenols fromFoods (Basel, Switzerland) · 2022Article
- Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?Cells · 2022Review
- Protocol for a mobile laboratory study of co-administration of cannabis concentrates with a standard alcohol dose in humans.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
rationalePublished studies examining the effects of cannabis have largely utilized forms of cannabis that are not representative of the legal market products currently available.
objectivesThe present study aimed to characterize naturalistic use of legal market flower and edible products by examining associations among blood cannabinoids and amount of THC consumed as well as physiological, cognitive, and subjective effects in users of edible and flower forms.
methodEighty-four participants who used cannabis at least 1 × /week (55 flower cannabis using participants; 29 edible cannabis using participants mean age = 31.95 years, 44% female) participated. At the experimental appointment in our mobile laboratory, participants completed a blood draw to assess plasma cannabinoids, measures of heart rate, subjective drug effects, and cognition both before and after ad libitum use of legal market flower or edible cannabis.
resultsAverage self-reported THC consumed was 15.97 mg (SD = 22.40) in edible users and 51.25 mg (SD = 45.23) in flower users. In the edible group, but not the flower group, strong correlations emerged between self-reported ad libitum THC consumed and plasma THC. Plasma THC was significantly higher after use of inhaled cannabis, but similar levels of plasma THC metabolites and similar levels of subjective intoxication and verbal memory impairment were observed in both flower and edible users.
conclusionsFindings support strong correlations among ad libitum THC consumed and THC plasma levels after edible cannabis use and suggest few differences in intoxication and impairment between edible and flower cannabis users after ad libitum use. This novel study provides important preliminary data on the pharmacology and effects of legal market edible cannabis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.